Learn more

JO DAEWOONG

Overview
  • Total Patents
    21
  • GoodIP Patent Rank
    116,035
About

JO DAEWOONG has a total of 21 patent applications. Its first patent ever was published in 2008. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are CELLIVERY THERAPEUTICS INC, MARKS JAMES D and JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO LTD.

Patent filings in countries

World map showing JO DAEWOONGs patent filings in countries

Patent filings per year

Chart showing JO DAEWOONGs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Jo Daewoong 21
#2 Choi Young Sil 8
#3 Choi Youngsil 4
#4 Lim Jung-Hee 4
#5 Kim Jihye 3
#6 Lee Kuysook 3
#7 Kang Se-Eun 2
#8 Lee Kuy Sook 2
#9 Park Kisuk 2
#10 Kim Chohyun 2

Latest patents

Publication Filing date Title
US2016083441A1 Development of Protein-Based Biotherapeutics That Penetrate Cell-Membrane and Induce Anti-Cancer Effect - Cell-Permeable Trefoil Factor 1 (CP-TFF1) in Gastrointestinal Track (GIT) Cancer, Polynucleotides Encoding The Same, and Anti-Cancer Compositions Comprising The Same
US2016068825A1 Development of Protein-Based Biotherapeutics That Penetrate Cell-Membrane and Induce Anti-Cancer Effect- Cell-Permeable Glutathione Peroxidase7 (CP-GPX7) in Gastrointestinal Track (GIT), Polynucleotides Encoding the Same, and Anti-Cancer Compositions Comprising the Same
US2016060314A1 Development of a Protein-Based Biotherapeutic Agent That Penetrates Cell-Membrane and Induces Anti-Tumor Effect in Solid Tumors - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Tumor Compositions Comprising the Same
US2017029798A1 Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
US2012122796A1 Cell permeable p53 recombinant protein, polynucleotide encoding the same, and anti-cancer composition containing the same as active ingredient